Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic.
Cole Eye Institute - Retina Service, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Curr Opin Ophthalmol. 2021 May 1;32(3):225-232. doi: 10.1097/ICU.0000000000000742.
To review the available data supporting the use of photobiomodulation therapy (PBT) in the treatment of age-related macular degeneration (AMD).
PBT might be used in treating nonexudative AMD. Limited evidence suggests that exudative AMD may also benefit from PBT.
The optimal device would deliver doses of 60 J/cm2 or more with a multiwavelength composition through the pupil over short treatment intervals. Safe upper limits have not been established. More studies are needed to evaluate the efficacy of PBT in treating exudative and nonexudative AMD.
回顾支持光生物调节疗法（PBT）治疗年龄相关性黄斑变性（AMD）的现有数据。
PBT 可用于治疗非渗出性 AMD。有限的证据表明，渗出性 AMD 也可能受益于 PBT。
最佳设备应为瞳孔内通过多波长组合以 60J/cm2 或更高剂量在短治疗间隔内输送。尚未确定安全上限。需要更多研究来评估 PBT 治疗渗出性和非渗出性 AMD 的疗效。
